<?xml version="1.0" encoding="UTF-8"?>
<ref id="B162-biomedicines-08-00060">
 <label>162.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Eissa</surname>
    <given-names>I.R.</given-names>
   </name>
   <name>
    <surname>Bustos-Villalobos</surname>
    <given-names>I.</given-names>
   </name>
   <name>
    <surname>Ichinose</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Matsumura</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Naoe</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Miyajima</surname>
    <given-names>N.</given-names>
   </name>
   <name>
    <surname>Morimoto</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Mukoyama</surname>
    <given-names>N.</given-names>
   </name>
   <name>
    <surname>Zhiwen</surname>
    <given-names>W.</given-names>
   </name>
   <name>
    <surname>Tanaka</surname>
    <given-names>M.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>The current status and future prospects of oncolytic viruses in clinical trials against melanoma, glioma, pancreatic, and breast cancers</article-title>
  <source>Cancers (Basel)</source>
  <year>2018</year>
  <volume>10</volume>
  <elocation-id>356</elocation-id>
  <pub-id pub-id-type="doi">10.3390/cancers10100356</pub-id>
 </element-citation>
</ref>
